Category: Research Administration

Posted on

How to Determine If NIGMS Might Fund Your Research

by
0 comments
This post is the first in a series outlining NIGMS research priorities, funding opportunities, and the grant application process for those not familiar with our Institute and its programs. We encourage you to share this series with others in your network, and to sign up to receive all future Feedback Loop posts delivered straight to your inbox.

We receive many questions from prospective applicants about getting NIGMS funding for their research: How do I know if my research fits within the scientific interests of NIGMS? What grant programs does the Institute offer? What are NIGMS’ research priorities? Whom do I talk to—and when—to learn more?

This post will help to answer those questions. And because it’s the first post in a new series from our staff, think of it as a primer for your initial interactions with us.

Continue reading “How to Determine If NIGMS Might Fund Your Research”
Posted on

Give Us Your Input on NIGMS’ Reorganization

by
0 comments

UPDATE: The video from this webinar is available.

NIGMS supports basic research that increases our understanding of biological processes and lays the foundation for advances in disease diagnosis, treatment, and prevention. NIGMS also supports research in specific clinical areas that affect multiple organ systems: anesthesiology and peri-operative pain; clinical pharmacology common to multiple drugs and treatments; and injury, critical illness, sepsis, and wound healing. We have five scientific divisions that support research, research training, and capacity building in a range of scientific fields.

Continue reading “Give Us Your Input on NIGMS’ Reorganization”
Posted on

Data Management and Sharing Plan Expectations for NIGMS Grantees

by and
0 comments

As you may be aware, NIH will implement a new policy to promote the sharing of scientific data. This policy, which will require NIH grantees to submit a data management and sharing (DMS) plan as part of a grant application, goes into effect January 25. NIGMS believes that, in general, most of our grantees already meet the new NIH policy requirements, which we explain more fully in a list of FAQs.

Sharing scientific data accelerates biomedical research discovery, in part, by enabling validation of research results, providing accessibility to high-value datasets, and promoting data reuse for future research studies. Submitting a DMS plan as part of a grant application will formalize what NIGMS principal investigators already do and make explicit their plans for sharing data with the larger scientific community. Most DMS plans are expected to be concise (no more than two pages), and a sample plan is available, with a final fillable version available soon.

NIH has developed a website with details about the policy, guidance, and implementation. If you have questions about this new requirement after reviewing our FAQs, please contact NIH DMS policy staff or your NIGMS program officer.

Posted on

Grants.gov Downtime: How This Impacts NIGMS September 2022 Applications

by
0 comments

Grants.gov is migrating to the cloud, resulting in a period of planned downtime for the website. Though necessary, the downtime will significantly impact preparing and submitting your grant applications to NIH. The Grants.gov system outage will begin on Friday, September 23, at 12:01 a.m. ET, and end on Thursday, September 29, at 11:59 p.m. ET.

In response to this system outage, application due dates falling between September 22 and September 30 will move to October 3. You can learn more about these deadlines in NOT-OD-22-190, as well as on the Grants.gov community blog and the NIH Office of Extramural Research website.

Continue reading “Grants.gov Downtime: How This Impacts NIGMS September 2022 Applications”
Posted on

NIGMS Institutional T32, T34, and K12 Grant Applicants: Don’t Get Caught With Noncompliance!

by , , and
0 comments

UPDATE: Learn more about noncompliance and withdrawal of applications by reading our Frequently Asked Questions.

We frequently come across compliance issues when reviewing NIGMS T32, T34, and K12 institutional training grant applications. We’re providing information to help applicants avoid the consequences of not following the funding opportunity announcement (FOA) instructions, which could result in the withdrawal of applications without review:

Continue reading “NIGMS Institutional T32, T34, and K12 Grant Applicants: Don’t Get Caught With Noncompliance!”
Posted on

Change in Receipt Dates for NIGMS Research on Interventions Program

by , , and
0 comments

We recently published a notice (NOT-GM-20-050) announcing a single receipt date each year for our Research to Understand and Inform Interventions that Promote the Research Careers of Individuals in Biomedical Sciences (R01/R35) program.

The purpose of the program is to better understand the factors (e.g., social and behavioral) contributing to the success of individuals pursuing independent academic biomedical research careers. It supports research to enhance evidence for effective, high-impact, scalable interventions that may be focused on training programs, psychosocial factors, critical career transition points, or institutional culture. Due in part to the small number of applications received in response to this funding opportunity, the change in the program’s receipt date will allow us to increase efficiencies in the grant application review process.

Continue reading “Change in Receipt Dates for NIGMS Research on Interventions Program”
Posted on

Changes to COBRE Phase 1 and Phase 2 Awards and Applications

by and
0 comments

We’d like to call your attention to a pair of recently published notices (NOT-GM-20-042 and NOT-GM-20-043) that address the unfavorable impact of the COVID-19 pandemic on institutions’ ability to recruit faculty investigators. In response to this, we’ve reduced the minimum number of research projects required for our Centers of Biomedical Research Excellence (COBRE) Phases 1 and 2 from three to two. Additionally, we’ll allow budget increases for recruitment costs and pilot projects. These changes apply to active awards and to applications submitted for new Phase 1 (PAR-19-313) and Phase 2 (PAR-19-312) funding opportunity announcements.

Continue reading “Changes to COBRE Phase 1 and Phase 2 Awards and Applications”
Posted on

Retiring Peer Review Site Visits for NIGMS Training Programs

by and
0 comments

At NIGMS, site visits have traditionally been part of the peer review process for some training program renewal applications. The visits, which generally happened every other renewal cycle for existing programs, were conducted by NIGMS staff and review panel members to gain additional information about the programs. For those of you who are program directors or peer reviewers of our undergraduate, graduate, and postdoctoral training programs, it may feel as if site visits went away a long time ago. This is because changes to most of our training programs required new application submissions (see our previous post), which resulted in a significant reduction in visits, followed by a complete stoppage in recent months due to the COVID-19 pandemic.

Continue reading “Retiring Peer Review Site Visits for NIGMS Training Programs”
Posted on

NIGMS Priorities for Small Business Development of Sepsis Diagnostics and Therapeutics

by
0 comments

Last summer, we published a notice of information on our priorities for sepsis research that applies to all active NIGMS funding opportunity announcements. We’ve now published a notice of special interest (NOT-GM 20-028) to promote early-stage research and development projects through the NIH SBIR/STTR program. 

We’re interested in receiving applications from small businesses or from small businesses and their academic partners that propose to develop novel tools and technologies for sepsis research, detection, and treatment. We’re specifically interested in diagnostic tools, predictive clinical algorithms, and technologies to facilitate molecular phenotyping of sepsis patients.

If you have any questions about NIGMS priorities for small business development of sepsis diagnostics and therapeutics, please contact me.